Anavex Lf SC Cmn (AVXL) 3.21 $AVXL Technical Roundup on

New Post Public Reply Private Reply Replies (0) Message Board

Aug 21, 2016 at 5:18 AM

Anavex Lf SC Cmn (AVXL) 3.21 $AVXL

Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics
PR Newswire - Wed Aug 17, 7:17AM CDT
Biotechnology is a risk-taking arena where investors either come out a winner or the other way around. The industry is involved in drug development and clinical researches that are intended to treat and cure various medical conditions. Stock-Callers.com takes a look at these equities and see how they performed at the closing bell on Tuesday, August 16, 2016: Anavex Life Sciences Corp. (NASDAQ: AVXL), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), StemCells Inc. (NASDAQ: STEM), and Aratana Therapeutics Inc. (NASDAQ: PETX). Access these companies' trade alerts for free by signing up now at: Sign up today and download for free the research reports for the stocks covered today at: http://stock-callers.com/registration
AVXL: 3.21 (-0.11), STEM: 1.24 (-0.42), PETX: 9.11 (+0.06), THLD: 0.87 (+0.09)

Anavex Reports Fiscal Third Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 11, 3:15PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(Nasdaq:AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer's trial for ANAVEX 2-73.
AVXL: 3.21 (-0.11)

Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
GlobeNewswire - Wed Jul 27, 12:00PM CDT
Sustained Response Through 31 Weeks for both Cognitive (MMSE) and Functional (ADCS-ADL) Measures
AVXL: 3.21 (-0.11)

Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.21 (-0.11), ANIP: 67.99 (-1.00), RTRX: 16.79 (-0.24), ACOR: 24.85 (-0.15)

Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
GlobeNewswire - Wed Jun 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's Office of Orphan Product Development has granted Orphan Drug Designation to ANAVEX 2-73 for the treatment of infantile spasms.
AVXL: 3.21 (-0.11)

Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 16.24 (+0.08), PACB: 8.88 (-0.23), AVXL: 3.21 (-0.11), PPHM: 0.36 (-0.01)

Market Has Not Yet Noticed Potential in Anavex Life Sciences (AVXL); Have You?
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:48AM CDT
Anavex Life Sciences is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
AVXL: 3.21 (-0.11)

Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2016.
AVXL: 3.21 (-0.11)

Could a Pill to Cure Alzheimer's Disease Become Available Soon?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 26, 3:22PM CDT
Image source: Anavex Life Sciences. Recently, two women in Melbourne with Alzheimer's disease found themselves able to complete complex tasks they haven't been capable of for some time. One woman found herself suddenly able to play the piano again,...
AVXL: 3.21 (-0.11)

4 Stocks That Are Making Huge Gains Today
ACCESSWIRE - Mon Apr 25, 9:45AM CDT
NEW YORK, NY / ACCESSWIRE / April 25, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Friday. TPUB, AVXL, NEOT and LGCY are on high breakout alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 1.66 (-0.02), TPUB: 13.96 (+0.17), AVXL: 3.21 (-0.11), NEOT: 0.87 (unch)

U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
GlobeNewswire - Fri Apr 08, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive preclinical data on sigma-1 agonist ANAVEX 3-71 (formerly AF710B). The results show a statistically significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71.
AVXL: 3.21 (-0.11)

Covered Call Alerts For Celldex Therapeutics, Anavex Life Sciences Corp, El Pollo Loco, First Solar, Dollar Tree and hundreds of other stocks Released By InvestorsObserver
PR Newswire - Fri Mar 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CLDX, AVXL, LOCO, FSLR and DLTR.
FSLR: 37.80 (+0.28), DLTR: 95.57 (-0.29), AVXL: 3.21 (-0.11), CLDX: 3.95 (-0.21), LOCO: 13.79 (+0.17), WTW: 11.19 (+0.15)

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Anavex Life Sciences Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Wed Feb 10, 3:26PM CST
Lundin Law PC announces a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company"

(NASDAQ: AVXL) concerning possible violations of federal securities laws between May 17, 2013 and December 28, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the February 29, 2016, lead plaintiff motion deadline.
AVXL: 3.21 (-0.11)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Anavex Life Sciences Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 29, 2016
BusinessWire - Wed Feb 10, 12:37PM CST
The following statement is being issued by Levi & Korsinsky, LLP:
AVXL: 3.21 (-0.11)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honeywell's Supply Line Snags Bait Class Action Risk

Stepping into the chaos of the stock market sometimes feels like opening Pandora's box—just when you think you've seen it all, something new tumbles out. This time around, it's Honeywell Aerospace (NasdaqGS: HONA) playing catch with hot coals, and a burning class-action lawsuit smolders in the air. Deadline Looms for Investors in Class Action Heads up, folks! If you've...

Ractigen's Breakthrough in DMD: RNA Activates Utrophin

Ractigen's New Fight Against Duchenne: A Personal Take When it comes to biotech advancements, I've seen enough breakthroughs to not get swayed easily. But Ractigen Therapeutics presenting their first-in-human data on RNA activation for Duchenne Muscular Dystrophy (DMD) kind of demands your attention. Folks, they're talking about a potential shift in handling this brutal...

Vatrer Power: Lithium Batteries Revolutionize Golf Carts

The humdrum world of golf carts just got a jolt of energy with lithium batteries entering the fray. Vatrer Power, the brain behind some nifty LiFePO4 lithium battery conversions, made some noise at this year's Golf Carting Expo & Dealer Summit in Charleston, South Carolina. Held at the North Charleston Convention Center, this trade show was the industry's premier...

Venice's Climate Challenge: Rising Seas, Sinking Lands

Sea Rise Isn’t Just a Statistics Problem The ordeal of rising seas isn't just about staring at numbers in some spreadsheet, it's a real-world gut punch that's knocking at Venice's door. This city, known for its stunning architecture and winding canals, now serves as the poster child for what happens when Mother Nature and human errors leave a place on the brink of...

Aetna's 2027 Medicare Plans: Comprehensive Outlook

Unpacking Aetna's Medicare Strategy for 2027 Look, if there's one thing you should keep tabs on, it's how Aetna isn't just coasting by in the healthcare arena. These folks are pushing forward with new options for 2027 that prove they're serious about making healthcare not just accessible, but affordable across the board. Aetna, backed by CVS Health (NYSE: CVS), is making...

Kal Plastics Showcases at Design-2-Part Expo

Kal Plastics Steps into the Limelight There's a buzz in the air, and it's all about Kal Plastics getting ready to strut their stuff at the Southern California Design-2-Part Show. Now, most folks probably don't spend their nights dreaming about thermoforming and pressure forming, but these guys sure make a case for it. They’ve got their eyes on impressing the crowd with...

Trading Platforms Poised for Billions by 2031

Forecasts and Fierce Digital Landscapes Just when you thought the online trading realm was getting saturated, the numbers are making it clear: there’s still room for growth—even explosive growth. The online trading platform market is eyeing a hike, jumping from a $11.65 billion valuation in 2025 to a projected $18.18 billion by 2031, according to Mordor Intelligence....

Govee Stirs Halloween Chills with New Sarah Gellar Ad

Lighting Up Halloween the Hollywood Way When it comes to Halloween, folks go nuts driving up the thrill factor at home, and boy, has Govee nailed it this time around. They've dragged Sarah Michelle Gellar into their spooky mix, transforming homes into eerie masterpieces. And let's face it, who better than the 'Buffy the Vampire Slayer' herself to stir those spine-tingling...

The Real Cost of Cabinet Decisions: Refinish or Replace?

Uncovering the Truth Behind Cabinet Decisions When it comes to sprucing up a kitchen, most folks overlook what's hanging on their walls already: those tired old cabinets. Now, are you looking at chucking them out the window for brand-new ones, or can a fresh coat of paint breathe new life into them? Well, that's where Melvin Jones, a painting virtuoso from Lexington,...